https://www.cdc.gov/nhsn/cdaportal/terminology/codesystem/cdcnhsn.html|2023-04
name
CDCNHSN
CDCNHSN
package
us.nlm.vsac@0.21.0
us.nlm.vsac@0.21.0
content
complete
complete
status
active
active
date
2023-06-01 04:00:00.0
2023-06-01 04:00:00.0
NHSN Surveillance System Codes
| code | display | definition | hierarchy |
|---|---|---|---|
| 1002-5 | Central line | ||
| 1003-3 | Permanent central line | ||
| 1005-8 | Temporary central line | ||
| 1006-6 | Central line including umbilical catheter | ||
| 1101-5 | Atlas-axis | ||
| 1102-3 | Atlas-axis/Cervical | ||
| 1103-1 | Cervical | ||
| 1104-9 | Cervical/Dorsal/Dorsolumbar | ||
| 1105-6 | Dorsal/Dorsolumbar | ||
| 1106-4 | Lumbar/Lumbosacral | ||
| 1116-3 | Umbilical | ||
| 1117-1 | Tunneled (dialysis) | ||
| 1118-9 | Tunneled (other than dialysis) | ||
| 1119-7 | Non-tunneled (dialysis) | ||
| 1120-5 | Non-tunneled (other than dialysis) | ||
| 1205-4 | Anterior and posterior | ||
| 1237-7 | Infection present at time of surgery (PATOS) | ||
| 1238-5 | Surgical site infection (SSI) detected using the NHSN ICD-code based admit and readmit SSI surveillance toolkit | ||
| 1239-3 | Revision associated with prior infection at index joint | ||
| 1306-0 | Report No Events: Infection Surveillance: MSSA | ||
| 1307-8 | Report No Events: LabID Event (All specimens): MSSA | ||
| 1308-6 | Report No Events: LabID Event (Blood specimens only): MSSA | ||
| 1309-4 | Active surgical site infection (SSI) detection method | ||
| 1311-0 | No location change | ||
| 1312-8 | Passive surgical site infection (SSI) detection method | ||
| 1313-6 | Report No Events: NICU: PedVAE: birth weight under 750 grams | ||
| 1314-4 | Report No Events: NICU: PedVAE: birth weight 751-1000 grams | ||
| 1316-9 | Report No Events: NICU: PedVAE: birth weight 1001-1500 grams | ||
| 1317-7 | Report No Events: NICU: PedVAE: birth weight 1501-2500 grams | ||
| 1318-5 | Report No Events: NICU: PedVAE: birth weight over 2500 grams | ||
| 1319-3 | Report No Events: NICU: PedVAE: Extremely preterm (<28 weeks) | ||
| 1321-9 | Review of patient's medical record | ||
| 1322-7 | Post-discharge surgeon survey | ||
| 1323-5 | Post-discharge patient letter | ||
| 1324-3 | Post-discharge patient phone call | ||
| 1325-0 | Cooperative infection prevention process between facilities | ||
| 1326-8 | Patient or caregiver contacts facility to report | ||
| 1327-6 | Patient returns to outpatient facility for follow-up | ||
| 1328-4 | Surgeon contacts facility to report | ||
| 1329-2 | Report from another facility (inpatient, health department, emergency department, etc.) | ||
| 1330-0 | Report No Events: NICU: PedVAE: Very preterm (28 to <32 weeks) | ||
| 1331-8 | Report No Events: NICU: PedVAE: Moderate to late preterm (32 to <37 weeks) | ||
| 1332-6 | Report No Events: NICU: PedVAE: Term (>=37 weeks) | ||
| 1333-4 | Number of episodes of mechanical ventilation (EMV) days | ||
| 1334-2 | Extremely preterm (<28 weeks) | ||
| 1335-9 | Very preterm (28 to <32 weeks) | ||
| 1336-7 | Moderate to late preterm (32 to <37 weeks) | ||
| 1337-5 | Term (>=37 weeks) | ||
| 1338-3 | Report No Events: ICU: PedVAE | ||
| 1339-1 | Report No Events: SCA: PedVAE | ||
| 1340-9 | Report No Events: Same Day Outcome Measures | ||
| 1341-7 | Report No Events: Antimicrobial Resistance (AR) | ||
| 1342-5 | Report No Events: UTI Event | ||
| 1343-3 | New Antibiotic Starts for UTI Indication | ||
| 1344-1 | Number of Urine Cultures Ordered | ||
| 1345-8 | Total Resident Days | ||
| 1346-6 | Number of units transfused: Cryoprecipitate: Pathogen Reduced Cryoprecipitated Fibrinogen Complex | ||
| 1347-4 | Number of discards: Cryoprecipitate: Pathogen Reduced Cryoprecipitated Fibrinogen Complex | ||
| 1369-8 | Resident days | ||
| 1370-6 | Resident admissions | ||
| 1371-4 | Number of admissions on C. difficile treatment | ||
| 1372-2 | Number of C. difficile treatment starts | ||
| 1373-0 | Date first admitted to facility | ||
| 1374-8 | Resident transferred from acute care facility in past 4 weeks | ||
| 1375-5 | Resident on antibiotic therapy for this specific organism at the time of transfer | ||
| 1406-8 | KPRO: Total: Total Primary | ||
| 1407-6 | KPRO: Total: Total Revision | ||
| 1408-4 | KPRO: Total: Partial Revision | ||
| 1409-2 | KPRO: Hemi: Partial Primary | ||
| 1411-8 | KPRO: Hemi: Total Revision | ||
| 1412-6 | KPRO: Hemi: Partial Revision | ||
| 1413-4 | HPRO: Total: Total Primary | ||
| 1414-2 | HPRO: Total: Total Revision | ||
| 1415-9 | HPRO: Total: Partial Revision | ||
| 1416-7 | HPRO: Hemi: Partial Primary | ||
| 1417-5 | HPRO: Hemi: Total Revision | ||
| 1418-3 | HPRO: Hemi: Partial Revision | ||
| 1419-1 | HPRO: Resurfacing: Total Primary | ||
| 1420-9 | HPRO: Resurfacing: Total Revision | ||
| 1421-7 | HPRO: Resurfacing: Partial Primary | ||
| 1422-5 | HPRO: Resurfacing: Partial Revision | ||
| 1505-7 | Post-discharge surveillance | ||
| 1510-7 | Admission (during the stay in which the surgery was performed) | ||
| 1516-4 | Readmission to facility where procedure was performed | ||
| 1517-2 | Readmission to facility other than where procedure was performed | ||
| 1601-4 | Breast abscess or mastitis | ||
| 1602-2 | Myocarditis or pericarditis | ||
| 1603-0 | Clinical sepsis | ||
| 1604-8 | Deep incisional primary surgical site infection (SSI) | ||
| 1605-5 | Deep incisional secondary surgical site infection (SSI) | ||
| 1606-3 | Vertebral disc space infection | ||
| 1607-1 | Ear or mastoid infection (otitis externa, otitis media, otitis interna, mastoiditis) | ||
| 1608-9 | Eye infection, other than conjunctivitis | ||
| 1609-7 | Gastrointestinal tract infection (esophagus, stomach, small and large bowel, and rectum) excluding gastroenteritis and appendicitis | ||
| 1610-5 | Intraabdominal infection, not specified elsewhere including gallbladder, bile ducts, liver (excluding viral hepatitis), spleen, pancreas, peritoneum, subphrenic or subdiaphragmatic space, or other intraabdominal tissue or area not specified elsewhere | ||
| 1611-3 | Intracranial infection (brain abscess, subdural or epidural infection, encephalitis) | ||
| 1612-1 | Joint or bursa infection | ||
| 1613-9 | Laboratory-confirmed bloodstream infection | ||
| 1614-7 | Other infections of lower respiratory tract, other than pneumonia | ||
| 1615-4 | Meningitis or ventriculitis | ||
| 1616-2 | Oral cavity infection (mouth, tongue, or gums) | ||
| 1617-0 | Other infections of the male or female reproductive tract (epididymis, testes, prostate, vagina, ovaries, uterus, or other deep pelvic tissues, excluding endometritis or vaginal cuff infections) | ||
| 1618-8 | Other infections of the urinary tract (kidney, ureter, bladder, urethra, or tissue surrounding the retroperitoneal or perinephric space) | ||
| 1619-6 | Spinal abscess without meningitis | ||
| 1620-4 | Superficial incisional primary surgical site infection (SSI) | ||
| 1621-2 | Superficial incisional secondary surgical site infection (SSI) | ||
| 1622-0 | Upper respiratory tract infection, pharyngitis, laryngitis, epiglottitis | ||
| 1623-8 | Arterial or venous infection | ||
| 1624-6 | Vaginal cuff infection | ||
| 1625-3 | Symptomatic UTI (SUTI) | ||
| 1626-1 | Pneumonia 1 (PNU1) | ||
| 1631-1 | Pneumonia 2 (PNU2) | ||
| 1632-9 | Pneumonia 3 (PNU3) | ||
| 1640-2 | Organ/space | ||
| 1641-0 | Number of admissions with an order for a prophylactic intravenous antibiotic that was administered on time | ||
| 1642-8 | Number of admissions with an order for a prophylactic intravenous antibiotic that was not administered on time | ||
| 1643-6 | Number of admissions with no order for a prophylactic intravenous antibiotic | ||
| 1644-4 | Total number of admissions with a primary CPT code in this procedure category | ||
| 1645-1 | Hospital transfer/admission | ||
| 1646-9 | Wrong site | ||
| 1647-7 | Wrong side | ||
| 1648-5 | Wrong patient | ||
| 1649-3 | Wrong implant | ||
| 1650-1 | Order for prophylactic intravenous antibiotic not administered on time | ||
| 1651-9 | Attending physician other than surgeon | ||
| 1652-7 | Admitting inpatient facility | ||
| 1653-5 | Routine follow-up at outpatient facility | ||
| 1654-3 | Patient or family member | ||
| 1656-8 | Infection first reported source | ||
| 1657-6 | Summary data reporting outpatient procedure component events at a facility | ||
| 1671-7 | Bronchitis or tracheitis | ||
| 1672-5 | Burn infection | ||
| 1673-3 | Decubitus ulcer infection | ||
| 1674-1 | Disseminated infection | ||
| 1675-8 | Infant pustulosis | ||
| 1676-6 | Newborn circumcision infection | ||
| 1677-4 | Soft tissue, muscle, lymph node, or salivary gland infection | ||
| 1792-1 | Multi-drug resistant organism (MDRO) infection | ||
| 1795-4 | C. difficile-associated disease (CDAD) infection | ||
| 1796-2 | Reproductive tract infection | ||
| 1797-0 | Infection of the ear, eyes, nose, or throat | ||
| 1798-8 | Bone or joint infection | ||
| 1814-3 | fidaxomicin | ||
| 1815-0 | dalbavancin | ||
| 1816-8 | tedizolid | ||
| 1817-6 | oritavancin | ||
| 1818-4 | ceftolozane / tazobactam | ||
| 1819-2 | isavuconazonium | ||
| 1820-0 | avibactam / ceftazidime | ||
| 1821-8 | delafloxacin | ||
| 1826-7 | Number of new episodes of mechanical ventilation (EMV) | ||
| 1827-5 | Number of patient days adjusted for MDRO reporting (for inpatient location) | ||
| 1828-3 | Number of admissions adjusted for MDRO reporting (for inpatient location) | ||
| 1829-1 | Number of encounters adjusted for MDRO reporting | ||
| 1830-9 | Number of patient days adjusted for C. difficile reporting (for inpatient location) | ||
| 1831-7 | Number of admissions adjusted for C. difficile reporting | ||
| 1832-5 | Number of encounters adjusted for C. difficile reporting | ||
| 1833-3 | Number of central line days | ||
| 1834-1 | Number of airway pressure release ventilation (APRV) days | ||
| 1851-5 | Number of patient days | ||
| 1852-3 | Number of ventilator days | ||
| 1853-1 | Number of urinary catheter days | ||
| 1854-9 | Number of central line days including umbilical catheter | ||
| 1856-4 | Number of patients meeting high risk criteria for influenza vaccination | ||
| 1857-2 | Number of patients previously vaccinated for influenza during current influenza season | ||
| 1858-0 | Number of patients meeting high risk criteria and previously vaccinated for influenza during current influenza season | ||
| 1859-8 | Number of patients meeting high risk criteria for influenza vaccination and offered influenza vaccination but declining for reasons other than medical contraindication | ||
| 1860-6 | Number of patients meeting high risk criteria and offered influenza vaccination but declining because of having medical contraindication | ||
| 1861-4 | Number of patients meeting high risk criteria and receiving vaccination during admission | ||
| 1862-2 | Number of admissions | ||
| 1863-0 | Number of encounters | ||
| 1864-8 | Number of observations in which hand hygiene was indicated | ||
| 1865-5 | Number of observations in which hand hygiene was performed | ||
| 1866-3 | Number of observations in which the use of gown and gloves was indicated | ||
| 1867-1 | Number of observations in which gown and gloves were used | ||
| 1870-5 | Timing of active surveillance testing (AST) | ||
| 1871-3 | Active surveillance testing (AST) eligible patients | ||
| 1872-1 | Number of patients eligible for monitoring at admission/transfer in | ||
| 1873-9 | Number of patients on which monitoring was performed at admission/transfer in | ||
| 1874-7 | Number of patients eligible for monitoring at discharge/transfer out | ||
| 1875-4 | Number of patients on which monitoring was performed at discharge/transfer out | ||
| 1876-2 | Number of prevalent cases identified by monitoring (clinical positive) | ||
| 1877-0 | Number of prevalent cases previously known | ||
| 1878-8 | Number of incident cases identified by monitoring (clinical positive) | ||
| 1879-6 | Summary data reporting catheter and ventilator use in a ICU/other | ||
| 1880-4 | Summary data reporting catheter and ventilator use in a SCA | ||
| 1881-2 | Summary data reporting catheter and ventilator use in a NICU | ||
| 1884-6 | Summary data reporting active surveillance testing (AST) | ||
| 1887-9 | Summary data reporting antimicrobial usage | ||
| 1888-7 | Number of total facility patient days (for inpatient location) | ||
| 1889-5 | Number of total facility admissions (for inpatient location) | ||
| 1890-3 | Number of total facility encounters (for outpatient location) | ||
| 1891-1 | Summary data reporting MDRO and CDI LabID Event for LTCF | ||
| 1901-8 | Not cultured | ||
| 1902-6 | Blood culture not done or no organisms detected in blood | ||
| 1903-4 | New onset/change in sputum | ||
| 1904-2 | New onset/worsening cough, dyspnea, tachypnea | ||
| 1905-9 | Other evidence of infection found | ||
| 1906-7 | Other signs and symptoms | ||
| 1907-5 | New onset or change in sputum, increased secretions or increased suctioning | ||
| 1908-3 | Bradycardia or tachycardia | ||
| 1909-1 | Occult or gross blood in stools (with no rectal fissure) | ||
| 1920-8 | Localized swelling | ||
| 1921-6 | Rales or bronchial breath sounds | ||
| 1922-4 | Wheezing, rales or rhonchi | ||
| 1923-3 | Greater than or equal to 5% bronchoalveolar lavage cells with bacteria | ||
| 1924-0 | Imaging test evidence of infection | ||
| 1925-7 | New or progressive and persistent infiltrate | ||
| 1926-5 | Pneumatoceles (in <=1 year old) | ||
| 1927-3 | One positive culture with >=100,000 cfu/ml with no more than 2 species of microorganisms | ||
| 1928-1 | Positive dipstick for leukocyte esterase or nitrate | ||
| 1929-9 | Greater than or equal to 2 positive urine cultures with >=100 cfu/ml of same uropathogen from non-voided specimen | ||
| 1930-7 | One positive culture with <=100,000 cfu/ml of a single uropathogen in patient being treated with an effective antimicrobial agent for UTI | ||
| 1931-5 | Greater than or equal to 2 positive urine cultures with >=100,000 cfu/ml with no more than 2 organisms | ||
| 1934-9 | Positive detection of viral antigen or antibody | ||
| 1935-6 | Fourfold rise in paired sera for pathogen | ||
| 1936-4 | Positive culture or microimmunofluorescence of Legionella species | ||
| 1937-2 | Legionella pneumophila serogroup 1 antigens in urine | ||
| 1938-0 | Fourfold rise in Legionella pneumophila antibody titer | ||
| 1939-8 | Matching positive blood and sputum cultures with Candida species | ||
| 1940-6 | Fungi or Pneumocystis carinii from lower respiratory tract specimen | ||
| 1941-4 | Other positive laboratory tests | ||
| 1942-2 | More than 15 colonies cultured from intravascular cannula tip using semi-quantitative culture method | ||
| 1943-0 | Positive Gram stain when culture is negative or not done | ||
| 1944-8 | Common commensal from >=2 blood cultures | ||
| 1946-3 | Organism(s) identified from pleural fluid | ||
| 1947-1 | Positive quantitative culture from lower respiratory tract (LRT) specimen | ||
| 1948-9 | Positive culture of virus or Chlamydia | ||
| 1949-7 | Positive PCR for Chlamydia or Mycoplasma | ||
| 1950-5 | Positive microimmunofluorescence test for Chlamydia | ||
| 1951-3 | Recognized pathogen from one or more blood cultures | ||
| 1952-1 | Positive culture | ||
| 1953-9 | Positive culture of pathogen | ||
| 1954-7 | Positive culture of skin contaminant | ||
| 1955-4 | Positive blood culture | ||
| 1956-2 | Histopathologic exam with abscess formation or lung parenchyma invasion by fungal hyphae | ||
| 1957-0 | Acute onset of diarrhea (liquid stools for >12 hours) | ||
| 1958-8 | Worsening gas exchange | ||
| 1959-6 | Apnea, tachypnea, nasal flaring with retraction of chest wall or grunting | ||
| 1960-4 | Pain or tenderness | ||
| 1962-0 | Physician institutes appropriate antimicrobial therapy | ||
| 1963-8 | Physician diagnosis of this event type | ||
| 1964-6 | Allogeneic hematopoietic stem cell transplant (allo-SCT) with grade >=3 gastrointestinal graft-versus-host disease (GI GVHD) | ||
| 1965-3 | Allogeneic hematopoietic stem cell transplant (allo-SCT) with diarrhea | ||
| 1966-1 | Positive culture from >=2 separate tissue or fluid samples from affected joint | ||
| 1967-9 | Incision deliberately opened or drained | ||
| 1968-7 | Sinus tract | ||
| 1969-5 | Catheter-graft hybrid | ||
| 1970-3 | Periprosthetic joint infection | ||
| 1971-1 | Acute pain, swelling, or tenderness of testes, epididymis, or prostate | ||
| 1972-9 | Urine not tested for white blood cells | ||
| 2010-7 | MDR-Acinetobacter | ||
| 2016-4 | CephR-Klebsiella | ||
| 2017-2 | CRE-Klebsiella | ||
| 2018-0 | CRE-E. coli | ||
| 2019-8 | CRE-Enterobacter | ||
| 2029-7 | C. difficile primary testing method used most often for this quarter | ||
| 2030-5 | Enzyme immunoassay (EIA) for toxin | ||
| 2031-3 | Cell cytotoxicity neutralization assay | ||
| 2032-1 | Nucleic acid amplification test (NAAT) | ||
| 2033-9 | Glutamate dehydrogenase (GDH) antigen plus enzyme immunoassay (EIA) for toxin | ||
| 2034-7 | Glutamate dehydrogenase (GDH) plus nucleic acid amplification test (NAAT) | ||
| 2035-4 | Glutamate dehydrogenase (GDH) plus enzyme immunoassay (EIA) for toxin, followed by nucleic acid amplification test (NAAT) for discrepant results | ||
| 2036-2 | Toxigenic culture | ||
| 2037-0 | Bacterial isolate tested for carbapenemase | ||
| 2039-6 | PCR: Klebsiella pneumoniae carbapenemase | ||
| 2040-4 | PCR: New Delhi metallo-beta-lactamase | ||
| 2041-2 | PCR: Imipenemase | ||
| 2042-0 | PCR: Verona integron-encoded metallo-beta-lactamase | ||
| 2043-8 | PCR: Oxacillinase-48 like | ||
| 2044-6 | Modified Hodge test | ||
| 2045-3 | Carba NP | ||
| 2046-1 | Metallo-beta-lactamase gradient strip | ||
| 2047-9 | Metallo-beta-lactamase screen | ||
| 2048-7 | Isolate tested positive for carbapenemase | ||
| 2049-5 | Carbapenemase type | ||
| 2050-3 | Klebsiella pneumoniae carbapenemase | ||
| 2051-1 | New Delhi metallo-beta-lactamase | ||
| 2052-9 | Imipenemase | ||
| 2053-7 | Verona integron-encoded metallo-beta-lactamase | ||
| 2054-5 | Oxacillinase-48-like | ||
| 2055-2 | Nonspecific carbapenemase activity | ||
| 2056-0 | Nonspecific metallo-beta-lactamase activity | ||
| 2057-8 | Nucleic acid amplification test (NAAT) plus enzyme immunoassay (EIA), if NAAT positive (2-step algorithm) | ||
| 2101-4 | Hip prosthesis | ||
| 2102-2 | Shunt for dialysis | ||
| 2103-0 | Not an NHSN operation | ||
| 2104-8 | Other operations | ||
| 2105-5 | Abdominal aortic aneurysm repair | ||
| 2106-3 | Herniorrhaphy | ||
| 2107-1 | Abdominal hysterectomy | ||
| 2108-9 | Appendix surgery | ||
| 2109-7 | Bile duct, liver or pancreatic surgery | ||
| 2110-5 | Breast surgery | ||
| 2111-3 | Cardiac surgery | ||
| 2112-1 | Coronary artery bypass graft with both chest and donor site incisions | ||
| 2113-9 | Coronary artery bypass graft with chest incision only | ||
| 2114-7 | Carotid endarterectomy | ||
| 2115-4 | Cesarean section | ||
| 2116-2 | Colon surgery | ||
| 2117-0 | Craniotomy | ||
| 2118-8 | Abdominal surgery | ||
| 2119-6 | Gallbladder surgery | ||
| 2120-4 | Gastric surgery | ||
| 2121-2 | Heart transplant | ||
| 2122-0 | Kidney surgery | ||
| 2123-8 | Kidney transplant | ||
| 2124-6 | Knee prosthesis | ||
| 2125-3 | Laminectomy | ||
| 2126-1 | Limb amputation | ||
| 2127-9 | Liver transplant | ||
| 2128-7 | Neck surgery | ||
| 2129-5 | Open reduction of fracture | ||
| 2130-3 | Ovarian surgery | ||
| 2131-1 | Pacemaker surgery | ||
| 2132-9 | Peripheral vascular bypass surgery | ||
| 2133-7 | Prostate surgery | ||
| 2134-5 | Rectal surgery | ||
| 2135-2 | Refusion of spine | ||
| 2136-0 | Small bowel surgery | ||
| 2137-8 | Spinal fusion | ||
| 2138-6 | Spleen surgery | ||
| 2139-4 | Thoracic surgery | ||
| 2140-2 | Thyroid and/or parathyroid surgery | ||
| 2141-0 | Vaginal hysterectomy | ||
| 2142-8 | Ventricular shunt | ||
| 2201-2 | On admission only | ||
| 2202-0 | On admission and on discharge/transfer | ||
| 2212-9 | PICC team | ||
| 2213-7 | Performer was a member of PICC/IV team | ||
| 2301-0 | All patients | ||
| 2302-8 | Only patients with no prior documentation of colonization or infection | ||
| 2303-6 | Contamination | ||
| 2304-4 | Transient patient | ||
| 2305-1 | Pus, redness, or increased swelling | ||
| 2306-9 | Intravenous injection of antifungal substance | ||
| 2307-7 | Imputability of positive blood culture to suspected source | ||
| 2308-5 | Buttonhole cannulation | ||
| 2310-1 | Number of chronic hemodialysis patients: fistula | ||
| 2311-9 | Number of fistula patients who undergo buttonhole cannulation | ||
| 2312-7 | Number of chronic hemodialysis patients: graft | ||
| 2313-5 | Number of chronic hemodialysis patients: tunneled central line | ||
| 2314-3 | Number of chronic hemodialysis patients: non-tunneled central line | ||
| 2315-0 | Number of chronic hemodialysis patients: other access device | ||
| 2316-8 | Summary data reporting vascular access types for chronic hemodialysis patients | ||
| 2318-4 | MDRO or C. difficile infection | ||
| 2319-2 | Vascular access | ||
| 2320-0 | Wound (not related to vascular access) with pus or increased redness | ||
| 2321-8 | Site of non-tunneled central line, dialysis | ||
| 2322-6 | Site of tunneled central line, dialysis | ||
| 2323-4 | Vascular site fistula | ||
| 2324-2 | Vascular site graft | ||
| 2325-9 | Loss of vascular access | ||
| 2331-7 | Where was the positive blood culture collected | ||
| 2332-5 | Hospital (on the day of or the day following admission) or Emergency Department | ||
| 2333-3 | Dialysis clinic | ||
| 2335-8 | New outpatient start or continuation of inpatient course | ||
| 2336-6 | New antibiotic start | ||
| 2337-4 | Continuation of antimicrobial | ||
| 2339-0 | Blood sample collected for culture | ||
| 2340-3 | Ventilator-associated event (VAE) | ||
| 2341-2 | Location of mechanical ventilation initiation | ||
| 2342-6 | Patient on airway pressure release ventilation (APRV) or a related mode of mechanical ventilation at the time of VAE | ||
| 2343-4 | Ventilator-associated condition (VAC) | ||
| 2344-2 | Infection-related ventilator-associated complication (IVAC) | ||
| 2345-0 | Possible ventilator-associated pneumonia (PVAP) | ||
| 2346-5 | Daily minimum FiO2 increase >=0.20 (20 points) for >=2 days | ||
| 2347-3 | Daily minimum PEEP increase >=3 cm H2O for >=2 days | ||
| 2348-1 | Temperature >38°C or <36°C | ||
| 2349-9 | White blood cell count >=12,000 or <=4,000 cells/mm3 | ||
| 2350-2 | A new antimicrobial agent(s) is started, and is continued for >=4 days | ||
| 2351-1 | Criterion 1: positive culture from endotracheal aspirate without purulent respiratory secretions | ||
| 2352-5 | Criterion 1: positive culture from bronchoalveolar lavage without purulent respiratory secretions | ||
| 2353-3 | Criterion 1: positive culture from lung tissue without purulent respiratory secretions | ||
| 2354-1 | Criterion 1: positive culture from protected specimen brush without purulent respiratory secretions | ||
| 2355-9 | Criterion 2: purulent respiratory secretions plus organism(s) | ||
| 2356-4 | Criterion 2: organisms from sputum culture with purulent respiratory secretions | ||
| 2357-2 | Criterion 2: organisms from endotracheal aspirate culture with purulent respiratory secretions | ||
| 2358-0 | Criterion 2: organisms from bronchoalveolar lavage culture with purulent respiratory secretions | ||
| 2359-8 | Criterion 2: organisms from lung tissue culture with purulent respiratory secretions | ||
| 2360-1 | Criterion 2: organisms from protected specimen brush culture with purulent respiratory secretions | ||
| 2361-0 | Criterion 3: positive test for organism(s) identified from pleural fluid | ||
| 2362-4 | Criterion 3: positive test for lung histopathology | ||
| 2363-2 | Criterion 3: positive diagnostic test for Legionella species | ||
| 2364-0 | Criterion 3: positive diagnostic test for selected viral pathogens | ||
| 2366-3 | Employees (staff on facility payroll) | ||
| 2367-1 | Licensed independent practitioners: physicians, advanced practice nurses, and physician assistants | ||
| 2368-9 | Adult students or trainees and volunteers | ||
| 2369-7 | Other contract personnel | ||
| 2402-6 | Asymptomatic bacteremic UTI (ABUTI) | ||
| 2403-4 | One positive culture with >=1,000 cfu/ml and <100,000 cfu/ml with no more than 2 species of microorganisms | ||
| 2404-2 | Removed within 48 hours prior | ||
| 2406-7 | Primary | ||
| 2407-5 | Other than primary | ||
| 2409-1 | Number of blood cultures performed | ||
| 2410-9 | Summary data reporting antimicrobial resistance patterns at a facility | ||
| 2500-7 | Blood product was implicated in the adverse reaction | ||
| 2501-5 | Case definition match | ||
| 2502-3 | Imputability of adverse reaction to transfusion | ||
| 2503-1 | Imputability of death to transfusion | ||
| 2504-9 | Received non-irradiated blood in the 2 months preceding the reaction | ||
| 2513-0 | Bilateral infiltrates on chest x-ray | ||
| 2514-8 | Diffuse hemorrhage | ||
| 2515-5 | Nausea/vomiting | ||
| 2516-3 | Criterion not otherwise specified | ||
| 2517-1 | Pain not otherwise specified | ||
| 2518-9 | Rash not otherwise specified | ||
| 2524-7 | Number of therapy days | ||
| 2525-4 | Number of patient-present days | ||
| 2543-7 | Hemovigilance module - monthly reporting denominator | ||
| 3002-3 | Last physical overnight location of patient immediately prior to arriving into facility | ||
| 3004-9 | Patient discharged from another facility in the past 4 weeks | ||
| 3005-6 | Nursing Home/Skilled Nursing Facility | ||
| 3006-4 | Other inpatient healthcare setting (e.g., Acute Care Hospital, LTAC, Rehabilitation, etc.) | ||
| 3007-2 | Personal residence/residential care | ||
| 3010-6 | Report No Events: ICU: CLABSI | ||
| 3011-4 | Report No Events: ICU: CAUTI | ||
| 3012-2 | Report No Events: ICU: VAE | ||
| 3013-0 | Report No Events: ICU: PedVAP | ||
| 3014-8 | Report No Events: NICU: CLABSI: under 750 grams | ||
| 3015-5 | Report No Events: NICU: CLABSI: 751-1000 grams | ||
| 3016-3 | Report No Events: NICU: CLABSI: 1001-1500 grams | ||
| 3017-1 | Report No Events: NICU: CLABSI: 1501-2500 grams | ||
| 3018-9 | Report No Events: NICU: CLABSI: over 2500 grams | ||
| 3019-7 | Report No Events: NICU: PedVAP: under 750 grams | ||
| 3020-5 | Report No Events: NICU: PedVAP: 751-1000 grams | ||
| 3021-3 | Report No Events: NICU: PedVAP: 1001-1500 grams | ||
| 3022-1 | Report No Events: NICU: PedVAP: 1501-2500 grams | ||
| 3023-9 | Report No Events: NICU: PedVAP: over 2500 grams | ||
| 3024-7 | Report No Events: SCA: TCLAB | ||
| 3025-4 | Report No Events: SCA: PCLAB | ||
| 3026-2 | Report No Events: SCA: CAUTI | ||
| 3027-0 | Report No Events: SCA: VAE | ||
| 3028-8 | Report No Events: SCA: PedVAP | ||
| 3029-6 | Report No Events: Infection Surveillance: MRSA | ||
| 3030-4 | Report No Events: LabID Event (All specimens): MRSA | ||
| 3031-2 | Report No Events: LabID Event (Blood specimens only): MRSA | ||
| 3032-0 | Report No Events: Infection Surveillance: VRE | ||
| 3033-8 | Report No Events: LabID Event (All specimens): VRE | ||
| 3034-6 | Report No Events: LabID Event (Blood specimens only): VRE | ||
| 3035-3 | Report No Events: Infection Surveillance: CephR Klebsiella | ||
| 3036-1 | Report No Events: LabID Event (All specimens): CephR Klebsiella | ||
| 3037-9 | Report No Events: LabID Event (Blood specimens only): CephR Klebsiella | ||
| 3038-7 | Report No Events: Infection Surveillance: CRE-E. coli | ||
| 3039-5 | Report No Events: LabID Event (All specimens): CRE-E. coli | ||
| 3040-3 | Report No Events: LabID Event (Blood specimens only): CRE-E. coli | ||
| 3041-1 | Report No Events: Infection Surveillance: CRE-Enterobacter | ||
| 3042-9 | Report No Events: LabID Event (All specimens): CRE-Enterobacter | ||
| 3043-7 | Report No Events: LabID Event (Blood specimens only): CRE-Enterobacter | ||
| 3044-5 | Report No Events: Infection Surveillance: CRE-Klebsiella | ||
| 3045-2 | Report No Events: LabID Event (All specimens): CRE-Klebsiella | ||
| 3046-0 | Report No Events: LabID Event (Blood specimens only): CRE-Klebsiella | ||
| 3047-8 | Report No Events: Infection Surveillance: MDR-Acinetobacter | ||
| 3048-6 | Report No Events: LabID Event (All specimens): MDR-Acinetobacter | ||
| 3049-4 | Report No Events: LabID Event (Blood specimens only): MDR-Acinetobacter | ||
| 3050-2 | Report No Events: Infection Surveillance: C. difficile | ||
| 3051-0 | Report No Events: LabID Event (All specimens): C. difficile | ||
| 3052-8 | Report No Events: Dialysis: intravenous antimicrobial start | ||
| 3053-6 | Report No Events: Dialysis: positive blood culture | ||
| 3054-4 | Report No Events: Dialysis: pus, redness, or increased swelling at vascular access site | ||
| 3055-1 | Known or suspected Munchausen syndrome by proxy during current admission | ||
| 3056-9 | Observed or suspected patient injection into vascular line(s) within the BSI infection window | ||
| 3057-7 | Epidermolysis bullosa during current admission | ||
| 3059-3 | Pus present at vascular specimen collection site and matching organism identified in blood and from site-specific specimen(s) | ||
| 3060-1 | Peripheral intravenous or midline catheter | ||
| 3061-9 | Atrial lines (right and left) | ||
| 3062-7 | Hemodialysis reliable outflow (HERO) catheter | ||
| 3063-5 | Intra-aortic balloon pump (IABP) device | ||
| 3064-3 | Non-accessed central line (not accessed nor inserted during the hospitalization) | ||
| 3066-8 | Neonatal Laboratory Confirmed Bloodstream Infection 1 (NLCBI 1) | ||
| 3067-6 | Neonatal Laboratory Confirmed Bloodstream Infection 2 (NLCBI 2) | ||
| 3068-4 | Neonatal Laboratory Confirmed Meningitis 1 (NLCM 1) | ||
| 3069-2 | Neonatal Laboratory Confirmed Meningitis 2 (NLCM 2) | ||
| 3070-0 | Common commensal from blood specimen(s) and antibiotics for >=5 days | ||
| 3071-8 | Recognized pathogen from cerebrospinal fluid specimen | ||
| 3072-6 | Common commensal from cerebrospinal fluid specimen and antibiotics for >=5 days | ||
| 3104-7 | Recorder was performer | ||
| 3108-8 | Central line insertion practice (CLIP) | ||
| 3109-6 | Hand hygiene | ||
| 3111-2 | Secondary bloodstream infection | ||
| 3114-6 | Solution(s) had dried | ||
| 3115-3 | Peripherally inserted central catheter (PICC) | ||
| 3119-7 | No pathogen identified | ||
| 3121-1 | Central line exchanged over guidewire | ||
| 3163-3 | Performs direct patient care | ||
| 3188-0 | Infection occurred post-procedure | ||
| 3189-8 | Non-autologous transplant | ||
| 3191-4 | Urinary catheter present | ||
| 3192-2 | Seasons immunized | ||
| 3193-0 | Active surveillance testing (AST) organism monitored | ||
| 3195-5 | Clinical specialty | ||
| 3300-1 | Birth weight under 750 grams | ||
| 3301-9 | Birth weight 751-1000 grams | ||
| 3302-7 | Birth weight 1001-1500 grams | ||
| 3303-5 | Birth weight 1501-2500 grams | ||
| 3304-3 | Birth weight over 2500 grams | ||
| 3305-0 | Number of temporary central line days | ||
| 3306-8 | Number of permanent central line days | ||
| 3401-7 | Total number of units transfused: Red Blood Cells: Whole blood-derived | ||
| 3402-5 | Total number of aliquots transfused: Red Blood Cells: Whole blood-derived | ||
| 3403-3 | Number of units transfused: Red Blood Cells: Whole blood-derived: Irradiated | ||
| 3404-1 | Number of aliquots transfused: Red Blood Cells: Whole blood-derived: Irradiated | ||
| 3405-8 | Number of units transfused: Red Blood Cells: Whole blood-derived: Leukocyte-reduced | ||
| 3406-6 | Number of aliquots transfused: Red Blood Cells: Whole blood-derived: Leukocyte-reduced | ||
| 3407-4 | Number of units transfused: Red Blood Cells: Whole blood-derived: Irradiated and leukocyte-reduced | ||
| 3408-2 | Number of aliquots transfused: Red Blood Cells: Whole blood-derived: Irradiated and leukocyte-reduced | ||
| 3409-0 | Total number of units transfused: Red Blood Cells: Apheresis | ||
| 3410-8 | Total number of aliquots transfused: Red Blood Cells: Apheresis | ||
| 3411-6 | Number of units transfused: Red Blood Cells: Apheresis: Irradiated | ||
| 3412-4 | Number of aliquots transfused: Red Blood Cells: Apheresis: Irradiated | ||
| 3413-2 | Number of units transfused: Red Blood Cells: Apheresis: Leukocyte-reduced | ||
| 3414-0 | Number of aliquots transfused: Red Blood Cells: Apheresis: Leukocyte-reduced | ||
| 3415-7 | Number of units transfused: Red Blood Cells: Apheresis: Irradiated or leukocyte-reduced | ||
| 3416-5 | Number of aliquots transfused: Red Blood Cells: Apheresis: Irradiated or leukocyte-reduced | ||
| 3417-3 | Total number of units transfused: Platelets: Whole blood-derived | ||
| 3418-1 | Number of units transfused: Platelets: Whole blood-derived: Irradiated | ||
| 3419-9 | Number of units transfused: Platelets: Whole blood-derived: Leukocyte-reduced | ||
| 3420-7 | Number of units transfused: Platelets: Whole blood-derived: Irradiated and leukocyte-reduced | ||
| 3421-5 | Total number of units transfused: Platelets: Apheresis | ||
| 3422-3 | Total number of aliquots transfused: Platelets: Apheresis | ||
| 3423-1 | Number of units transfused: Platelets: Apheresis: Irradiated | ||
| 3424-9 | Number of aliquots transfused: Platelets: Apheresis: Irradiated | ||
| 3425-6 | Number of units transfused: Platelets: Apheresis: Leukocyte-reduced | ||
| 3426-4 | Number of aliquots transfused: Platelets: Apheresis: Leukocyte-reduced | ||
| 3427-2 | Number of units transfused: Platelets: Apheresis: Irradiated or leukocyte-reduced | ||
| 3428-0 | Number of aliquots transfused: Platelets: Apheresis: Irradiated or leukocyte-reduced | ||
| 3429-8 | Total number of units transfused: Plasma: Whole blood-derived | ||
| 3430-6 | Total number of aliquots transfused: Plasma: Whole blood-derived | ||
| 3431-4 | Total number of units transfused: Plasma: Apheresis | ||
| 3432-2 | Total number of aliquots transfused: Plasma: Apheresis | ||
| 3433-0 | Total number of units transfused: Cryoprecipitate | ||
| 3436-3 | Number of patient samples collected for type and screen or crossmatch | ||
| 3467-8 | Total number of units transfused: Whole Blood | ||
| 3468-6 | Total number of aliquots transfused: Whole Blood | ||
| 3469-4 | Total number of discards: Whole Blood | ||
| 3470-2 | Total number of discards: Red Blood Cells: Whole blood-derived | ||
| 3471-0 | Number of units transfused: Red Blood Cells: Whole blood-derived: Not irradiated or leukocyte-reduced | ||
| 3472-8 | Number of aliquots transfused: Red Blood Cells: Whole blood-derived: Not irradiated or leukocyte-reduced | ||
| 3473-6 | Number of discards: Red Blood Cells: Whole blood-derived: Not irradiated or leukocyte-reduced | ||
| 3474-4 | Number of discards: Red Blood Cells: Whole blood-derived: Irradiated | ||
| 3475-1 | Number of discards: Red Blood Cells: Whole blood-derived: Leukocyte-reduced | ||
| 3476-9 | Number of discards: Red Blood Cells: Whole blood-derived: Irradiated and leukocyte-reduced | ||
| 3477-7 | Total number of discards: Red Blood Cells: Apheresis | ||
| 3478-5 | Number of units transfused: Red Blood Cells: Apheresis: Not irradiated or leukocyte-reduced | ||
| 3479-3 | Number of aliquots transfused: Red Blood Cells: Apheresis: Not irradiated or leukocyte-reduced | ||
| 3480-1 | Number of discards: Red Blood Cells: Apheresis: Not irradiated or leukocyte-reduced | ||
| 3481-9 | Number of discards: Red Blood Cells: Apheresis: Irradiated | ||
| 3482-7 | Number of discards: Red Blood Cells: Apheresis: Leukocyte-reduced | ||
| 3483-5 | Number of discards: Red Blood Cells: Apheresis: Irradiated or leukocyte-reduced | ||
| 3484-3 | Total number of discards: Platelets: Whole blood-derived | ||
| 3485-0 | Number of units transfused: Platelets: Whole blood-derived: Not irradiated or leukocyte-reduced | ||
| 3486-8 | Number of discards: Platelets: Whole blood-derived: Not irradiated or leukocyte-reduced | ||
| 3487-6 | Number of discards: Platelets: Whole blood-derived: Irradiated | ||
| 3488-4 | Number of discards: Platelets: Whole blood-derived: Leukocyte-reduced | ||
| 3489-2 | Number of discards: Platelets: Whole blood-derived: Irradiated and leukocyte-reduced | ||
| 3490-0 | Total number of discards: Platelets: Apheresis | ||
| 3491-8 | Number of units transfused: Platelets: Apheresis: Not irradiated or leukocyte-reduced | ||
| 3492-6 | Number of aliquots transfused: Platelets: Apheresis: Not irradiated or leukocyte-reduced | ||
| 3493-4 | Number of discards: Platelets: Apheresis: Not irradiated or leukocyte-reduced | ||
| 3494-2 | Number of discards: Platelets: Apheresis: Irradiated | ||
| 3495-9 | Number of discards: Platelets: Apheresis: Leukocyte-reduced | ||
| 3496-7 | Number of discards: Platelets: Apheresis: Irradiated or leukocyte-reduced | ||
| 3497-5 | Total number of discards: Plasma: Whole blood-derived | ||
| 3498-3 | First discovery | ||
| 3499-1 | Number of adverse reactions | ||
| 3500-6 | Total number of discards: Plasma: Apheresis | ||
| 3501-4 | Total number of discards: Cryoprecipitate | ||
| 3502-2 | Total number of units transfused: Platelets: Whole blood-derived: Psoralen- and Riboflavin-treated | ||
| 3504-8 | Total number of discards: Platelets: Whole blood-derived: Psoralen- and Riboflavin-treated | ||
| 3505-5 | Number of units transfused: Platelets: Whole blood-derived: Psoralen-treated | ||
| 3507-1 | Number of discards: Platelets: Whole blood-derived: Psoralen-treated | ||
| 3508-9 | Number of units transfused: Platelets: Whole blood-derived: Riboflavin-treated | ||
| 3510-5 | Number of discards: Platelets: Whole blood-derived: Riboflavin-treated | ||
| 3511-3 | Total number of units transfused: Platelets: Apheresis: Psoralen- and Riboflavin-treated | ||
| 3512-1 | Total number of aliquots transfused: Platelets: Apheresis: Psoralen- and Riboflavin-treated | ||
| 3513-9 | Total number of discards: Platelets: Apheresis: Psoralen- and Riboflavin-treated | ||
| 3514-7 | Number of units transfused: Platelets: Apheresis: Psoralen-treated | ||
| 3515-4 | Number of aliquots transfused: Platelets: Apheresis: Psoralen-treated | ||
| 3516-2 | Number of discards: Platelets: Apheresis: Psoralen-treated | ||
| 3517-0 | Number of units transfused: Platelets: Apheresis: Riboflavin-treated | ||
| 3518-8 | Number of aliquots transfused: Platelets: Apheresis: Riboflavin-treated | ||
| 3519-6 | Number of discards: Platelets: Apheresis: Riboflavin-treated | ||
| 3520-4 | Total number of units transfused: Plasma: Whole blood-derived: Psoralen- and Riboflavin-treated | ||
| 3521-2 | Total number of aliquots transfused: Plasma: Whole blood-derived: Psoralen- and Riboflavin-treated | ||
| 3522-0 | Total number of discards: Plasma: Whole blood-derived: Psoralen- and Riboflavin-treated | ||
| 3523-8 | Number of units transfused: Plasma: Whole blood-derived: Psoralen-treated | ||
| 3524-6 | Number of aliquots transfused: Plasma: Whole blood-derived: Psoralen-treated | ||
| 3525-3 | Number of discards: Plasma: Whole blood-derived: Psoralen-treated | ||
| 3526-1 | Number of units transfused: Plasma: Whole blood-derived: Riboflavin-treated | ||
| 3527-9 | Number of aliquots transfused: Plasma: Whole blood-derived: Riboflavin-treated | ||
| 3528-7 | Number of discards: Plasma: Whole blood-derived: Riboflavin-treated | ||
| 3529-5 | Total number of units transfused: Plasma: Apheresis: Psoralen- and Riboflavin-treated | ||
| 3530-3 | Total number of aliquots transfused: Plasma: Apheresis: Psoralen- and Riboflavin-treated | ||
| 3531-1 | Total number of discards: Plasma: Apheresis: Psoralen- and Riboflavin-treated | ||
| 3532-9 | Number of units transfused: Plasma: Apheresis: Psoralen-treated | ||
| 3533-7 | Number of aliquots transfused: Plasma: Apheresis: Psoralen-treated | ||
| 3534-5 | Number of discards: Plasma: Apheresis: Psoralen-treated | ||
| 3535-2 | Number of units transfused: Plasma: Apheresis: Riboflavin-treated | ||
| 3536-0 | Number of aliquots transfused: Plasma: Apheresis: Riboflavin-treated | ||
| 3537-8 | Number of discards: Plasma: Apheresis: Riboflavin-treated | ||
| 3538-6 | Total crossmatch procedures | ||
| 3539-4 | Total patients transfused | ||
| 3540-2 | No hemovigilance adverse reactions reported this month | ||
| 3541-0 | No hemovigilance incidents reported this month | ||
| 3542-8 | Facility transfuses blood products treated with pathogen reduction technology | ||
| 3544-4 | Total number of units transfused: Red Blood Cells: Whole blood-derived: S-303- and Riboflavin-treated | ||
| 3545-1 | Total number of aliquots transfused: Red Blood Cells: Whole blood-derived: S-303- and Riboflavin-treated | ||
| 3546-9 | Total number of discards: Red Blood Cells: Whole blood-derived: S-303- and Riboflavin-treated | ||
| 3547-7 | Number of units transfused: Red Blood Cells: Whole blood-derived: S-303-treated | ||
| 3548-5 | Number of aliquots transfused: Red Blood Cells: Whole blood-derived: S-303-treated | ||
| 3549-3 | Number of discards: Red Blood Cells: Whole blood-derived: S-303-treated | ||
| 3550-1 | Number of units transfused: Red Blood Cells: Whole blood-derived: Riboflavin-treated | ||
| 3551-9 | Number of aliquots transfused: Red Blood Cells: Whole blood-derived: Riboflavin-treated | ||
| 3552-7 | Number of discards: Red Blood Cells: Whole blood-derived: Riboflavin-treated | ||
| 3553-5 | Total number of units transfused: Red Blood Cells: Apheresis: S-303- and Riboflavin-treated | ||
| 3554-3 | Total number of aliquots transfused: Red Blood Cells: Apheresis: S-303- and Riboflavin-treated | ||
| 3555-0 | Total number of discards: Red Blood Cells: Apheresis: S-303- and Riboflavin-treated | ||
| 3556-8 | Number of units transfused: Red Blood Cells: Apheresis: S-303-treated | ||
| 3557-6 | Number of aliquots transfused: Red Blood Cells: Apheresis: S-303-treated | ||
| 3558-4 | Number of discards: Red Blood Cells: Apheresis: S-303-treated | ||
| 3559-2 | Number of units transfused: Red Blood Cells: Apheresis: Riboflavin-treated | ||
| 3560-0 | Number of aliquots transfused: Red Blood Cells: Apheresis: Riboflavin-treated | ||
| 3561-8 | Number of discards: Red Blood Cells: Apheresis: Riboflavin-treated | ||
| 3562-6 | Total number of units transfused: Cryoprecipitate: Psoralen- and Riboflavin-treated | ||
| 3563-4 | Total number of discards: Cryoprecipitate: Psoralen- and Riboflavin-treated | ||
| 3564-2 | Number of units transfused: Cryoprecipitate: Psoralen-treated | ||
| 3565-9 | Number of discards: Cryoprecipitate: Psoralen-treated | ||
| 3566-7 | Number of units transfused: Cryoprecipitate: Riboflavin-treated | ||
| 3567-5 | Number of discards: Cryoprecipitate: Riboflavin-treated | ||
| 3568-3 | Number of units transfused: Platelets: Apheresis: Psoralen-treated and in plasma | ||
| 3569-1 | Number of aliquots transfused: Platelets: Apheresis: Psoralen-treated and in plasma | ||
| 3570-9 | Number of discards: Platelets: Apheresis: Psoralen-treated and in plasma | ||
| 3571-7 | Number of units transfused: Platelets: Apheresis: Psoralen-treated and in platelet additive solution | ||
| 3572-5 | Number of aliquots transfused: Platelets: Apheresis: Psoralen-treated and in platelet additive solution | ||
| 3573-3 | Number of discards: Platelets: Apheresis: Psoralen-treated and in platelet additive solution | ||
| 3574-1 | Number of units transfused: Platelets: Apheresis: Riboflavin-treated and in plasma | ||
| 3575-8 | Number of aliquots transfused: Platelets: Apheresis: Riboflavin-treated and in plasma | ||
| 3576-6 | Number of discards: Platelets: Apheresis: Riboflavin-treated and in plasma | ||
| 3577-4 | Number of units transfused: Platelets: Apheresis: Riboflavin-treated and in platelet additive solution | ||
| 3578-2 | Number of aliquots transfused: Platelets: Apheresis: Riboflavin-treated and in platelet additive solution | ||
| 3579-0 | Number of discards: Platelets: Apheresis: Riboflavin-treated and in platelet additive solution | ||
| 4100-4 | IV team | ||
| 4101-2 | Physician assistant | ||
| 4102-0 | Medical staff not otherwise specified | ||
| 4103-8 | Fellow | ||
| 5105-2 | To address a new indication for a central line | ||
| 5106-0 | To replace an existing, malfunctioning central line | ||
| 5107-8 | To replace an existing central line where infection was suspected | ||
| 6110-1 | Mask | ||
| 6111-9 | Sterile gown | ||
| 6112-7 | Large sterile drape | ||
| 6113-5 | Sterile gloves | ||
| 6122-6 | Cap | ||
| 6130-9 | Contraindication type | ||
| 6131-7 | Patient is less than 2 months of age - chlorhexidine gluconate is to be used with caution in patients less than 2 months of age | ||
| 6132-5 | Patient has a documented/known allergy/reaction to chlorhexidine gluconate-based products that would preclude its use | ||
| 6133-3 | Facility restrictions or safety concerns for chlorhexidine gluconate use in premature infants precludes its use | ||
| 6140-8 | Antimicrobial-coated catheter used |